Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Facchinetti · SciRah

Researcher profile · Semantic Scholar

F. Facchinetti

Share profile

F. Facchinetti — researcher profile on SciRah

h-index: 34
Works: 155
Citations: 4,091

Most-cited papers

Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
G. Recondo, L. Mezquita, F. Facchinetti, D. Planchard +37 more
2019Clinical Cancer Research156 citations Open access
Semantic Scholar
The Clinical Landscape of Cell-Free DNA Alterations in 1,671 Patients with Advanced Biliary Tract Cancer.
J. Berchuck, F. Facchinetti, D. Ditoro, I. Baiev +25 more
2022Annals of Oncology135 citations Open access
Semantic Scholar
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
F. Facchinetti, G. Mazzaschi, F. Barbieri, F. Passiglia +37 more
2020European Journal of Cancer135 citations Open access
Semantic Scholar
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
G. Mazzaschi, F. Facchinetti, G. Missale, D. Canetti +11 more
2019Lung Cancer101 citations
Semantic Scholar
Facts and new hopes on selective FGFR inhibitors in solid tumors
F. Facchinetti, A. Hollebecque, R. Bahleda, Y. Loriot +3 more
2019Clinical Cancer Research90 citations Open access
Semantic Scholar
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.
F. Facchinetti, L. Lacroix, L. Mezquita, J. Scoazec +15 more
2020European Journal of Cancer88 citations Open access
Semantic Scholar
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
R. Chiari, B. Ricciuti, L. Landi, A. Morelli +11 more
2020Clinical Lung Cancer87 citations
Semantic Scholar
Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges
A. Leonetti, F. Facchinetti, R. Minari, A. Cortellini +3 more
2019Cellular Oncology73 citations Open access
Semantic Scholar
New pathways in immune stimulation: targeting OX40
Carolina Alves Costa Silva, F. Facchinetti, B. Routy, L. Derosa
2020ESMO Open71 citations Open access
Semantic Scholar
Antibiotic-exposed patients with non-small cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
A. Cortellini, B. Ricciuti, F. Facchinetti, J. Alessi +22 more
2021Annals of Oncology66 citations Open access
Semantic Scholar
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis
F. Passiglia, M. Cinquini, L. Bertolaccini, M. Del Re +12 more
2021Journal of Clinical Oncology62 citations Open access
Semantic Scholar
Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer
F. Facchinetti, A. Hollebecque, F. Brayé, D. Vasseur +18 more
2023Cancer Discovery60 citations Open access
Semantic Scholar
Deubiquitinase USP5 promotes non-small cell lung cancer cell proliferation by stabilizing cyclin D1
Zhiwei Zhang, Zihan Cui, Zhuolin Xie, Chang Li +10 more
2021Translational Lung Cancer Research56 citations Open access
Semantic Scholar
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
F. Dall'Olio, F. Abbati, F. Facchinetti, M. Massucci +6 more
2020Therapeutic Advances in Medical Oncology55 citations Open access
Semantic Scholar
Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials
F. Facchinetti, M. di Maio, M. Tiseo
2020Cancers54 citations Open access
Semantic Scholar
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis
F. Facchinetti, M. di Maio, F. Perrone, M. Tiseo
2021Translational Lung Cancer Research40 citations Open access
Semantic Scholar
Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients.
J. Chen, F. Facchinetti, F. Brayé, A. Yurchenko +18 more
2022Annals of Oncology38 citations Open access
Semantic Scholar
Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies
F. Facchinetti, Y. Loriot, F. Brayé, D. Vasseur +16 more
2024Clinical Cancer Research35 citations Open access
Semantic Scholar
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
G. Guaitoli, M. Tiseo, M. di Maio, L. Friboulet +1 more
2021Translational Lung Cancer Research34 citations Open access
Semantic Scholar
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
A. Cortellini, B. Ricciuti, V. Vaz, D. Soldato +31 more
2022Journal for ImmunoTherapy of Cancer32 citations Open access
Semantic Scholar
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors
A. Leonetti, F. Facchinetti, T. Zielli, Elena Brianti +1 more
2020European Journal of Cancer31 citations Open access
Semantic Scholar
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines.
F. Passiglia, L. Bertolaccini, M. Del Re, F. Facchinetti +10 more
2020Critical reviews in oncology/hematology31 citations
Semantic Scholar
Non-small-cell lung cancer: how to manage BRAF-mutated disease
G. Guaitoli, L. Zullo, M. Tiseo, M. Dankner +2 more
2023Drugs in Context30 citations Open access
Semantic Scholar
Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis.
J. Remon, G. Villacampa, F. Facchinetti, M. di Maio +5 more
2022European Journal of Cancer29 citations Open access
Semantic Scholar
Exploring the Role of Respiratory Microbiome in Lung Cancer: a Systematic Review.
F. Perrone, L. Belluomini, M. Mazzotta, M. Bianconi +15 more
2021Critical reviews in oncology/hematology29 citations
Semantic Scholar
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
G. Recondo, L. Mahjoubi, A. Maillard, Y. Loriot +30 more
2020npj Precision Oncology27 citations Open access
Semantic Scholar
Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.
C. Ricordel, L. Friboulet, F. Facchinetti, J. Soria
2019Annals of Oncology25 citations Open access
Semantic Scholar
Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma
A. Dormieux, L. Mezquita, P. Cournède, J. Remon +17 more
2020European Radiology24 citations Open access
Semantic Scholar
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
Monia Sisi, M. Fusaroli, A. De Giglio, F. Facchinetti +3 more
2022Targeted oncology23 citations Open access
Semantic Scholar
Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
D. Enrico, L. Lacroix, Jeanne K. Chen, E. Rouleau +18 more
2020JTO Clinical and Research Reports22 citations Open access
Semantic Scholar
Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
F. Facchinetti, L. Friboulet
2019Lung Cancer22 citations Open access
Semantic Scholar
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer
Giuseppe Lo Russo, F. Facchinetti, M. Tiseo, M. Garassino +1 more
2020Current Oncology Reports21 citations
Semantic Scholar
Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer
H. Tao, Fang-Fang Li, Dong-Xiao Wu, Shi-Meng Ji +7 more
2022Translational Lung Cancer Research20 citations Open access
Semantic Scholar
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy
G. Mazzaschi, A. Leonetti, R. Minari, L. Gnetti +3 more
2021Current Treatment Options in Oncology19 citations
Semantic Scholar
Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy
G. Banna, M. Tiseo, D. Cortinovis, F. Facchinetti +30 more
2021Thoracic Cancer17 citations Open access
Semantic Scholar
The presence of lepidic and micropapillary/solid pathological patterns as minor components has prognostic value in patients with intermediate-grade invasive lung adenocarcinoma
Yucheng Hou, Weijian Song, Ming-Zhi Chen, Jianfeng Zhang +5 more
2021Translational Lung Cancer Research17 citations Open access
Semantic Scholar
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients
D. Vasseur, A. Arbab, Fabiola Giudici, C. Marzac +22 more
2024npj Precision Oncology16 citations Open access
Semantic Scholar
Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer.
S. E. Rebuzzi, A. Leonetti, M. Tiseo, F. Facchinetti
2019Immunotherapy15 citations Open access
Semantic Scholar
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)
F. Facchinetti, Sara Pilotto, G. Metro, E. Baldini +12 more
2019Tumori14 citations
Semantic Scholar
Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone Matters.
A. Cortellini, F. Facchinetti, L. Derosa, D. Pinato
2022Journal of Thoracic Oncology12 citations Open access
Semantic Scholar
Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial
A. Camerini, A. Del Conte, A. Pezzuto, V. Scotti +9 more
2022Cancers12 citations Open access
Semantic Scholar
The efficacy of immune checkpoint inhibitors in thoracic malignancies
J. Remon, F. Facchinetti, B. Besse
2021European Respiratory Review12 citations Open access
Semantic Scholar
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development
D. Vasseur, L. Bigot, K. Beshiri, J. Florez-Arango +26 more
2024Molecular Cancer11 citations Open access
Semantic Scholar
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
R. Minari, F. Bonatti, G. Mazzaschi, A. Dodi +14 more
2021Tumori11 citations
Semantic Scholar
Systemic thromboembolism from a misdiagnosed non-bacterial thrombotic endocarditis in a patient with lung cancer: A case report
F. Perrone, Andrea Biagi, F. Facchinetti, F. Bozzetti +7 more
2020Oncology Letters11 citations Open access
Semantic Scholar
Bilateral Severe Corneal Ulcer in a Patient with Lung Adenocarcinoma Treated with Gefitinib
F. Gozzi, M. Tiseo, F. Facchinetti, S. Gandolfi +1 more
2021Case Reports in Ophthalmology10 citations Open access
Semantic Scholar
Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
F. Facchinetti, A. Lévy, S. Ammari, C. Naltet +5 more
2021Cancer Management and Research9 citations Open access
Semantic Scholar
Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy
F. Zito Marino, Greta Alì, F. Facchinetti, L. Righi +3 more
2021Expert Review of Anticancer Therapy9 citations
Semantic Scholar
1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)
R. Ferrara, F. Facchinetti, G. Calareso, I. Kasraoui +16 more
20209 citations Open access
Semantic Scholar
Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?
F. Facchinetti, M. Majori, M. Sabato, L. Gnetti +1 more
2019Immunotherapy8 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Tiseo×21
Invite
M. Tiseo — researcher profile on SciRah
B. Besse×16
Invite
B. Besse — researcher profile on SciRah
L. Friboulet×14
Invite
L. Friboulet — researcher profile on SciRah
D. Planchard×9
Invite
D. Planchard — researcher profile on SciRah

×9

Invite

L. Tselikas — researcher profile on SciRah

A. Hollebecque×8

Invite

A. Hollebecque — researcher profile on SciRah

Invite

K. Olaussen — researcher profile on SciRah

Invite

L. Mezquita — researcher profile on SciRah

Invite

A. Gazzah — researcher profile on SciRah

Invite

L. Bigot — researcher profile on SciRah

Invite

S. Michiels — researcher profile on SciRah

Invite

L. Lacroix — researcher profile on SciRah